Exciting Advances in Heart Valve Research by Jenscare
Jenscare Scientific Co., Ltd. (HKEX: 9877), an innovative leader in medical devices, has recently unveiled significant results from their clinical studies involving the LuX-Valve Plus and JensClip systems. These promising findings were presented at EuroPCR 2025, highlighting advancements in treating severe heart valve conditions.
30-Day Insights from the LuX-Valve Plus Study
The TRINITY trial examined the LuX-Valve Plus, focusing on its performance in patients suffering from severe tricuspid regurgitation and high surgical risk factors. This global study involved 161 patients from 20 clinical centers, contributing to a wealth of data regarding their health outcomes.
The average age of participants in the study was 77 years, with many facing complex health issues. Notably, over 75% of the patients required valve sizes varying from 55mm to 70mm. Remarkably, the results indicated a device success rate of about 97%. The average time taken for the procedure was 41.6 minutes, with remarkable efficiency in operation time.
Safety assessments revealed that 30-day composite event rates were recorded at approximately 14.8% for the full analysis set (FAS) group and 14.9% when including the roll-in data. More impressively, 1.3% of patients experienced cardiovascular mortality, indicating strong overall safety. Other significant complications like major vascular issues and device-related pulmonary events remained absent.
Impressive Efficacy Outcomes
Efficacy was prominently highlighted, showing a significant reduction in tricuspid regurgitation (TR) grade and improved quality of life among patients. For the FAS group, 95.7% exhibited no significant TR after the intervention. This progress is highly encouraging, showcasing the potential of the LuX-Valve Plus in enhancing patient well-being.
Professor Thomas Modine, an authority in the field, affirmed the LuX-Valve Plus as a breakthrough device, praising its design features aimed at improving safety and efficacy. Expectations for lower demands on imaging quality may streamline overall treatment times, and with continued observation of the data, Jenscare is set to make further advancements in heart valve treatments.
One-Year Outcomes for the JensClip System
The JensClip system, dedicated to treating degenerative mitral regurgitation (DMR), also delivered promising findings. The study encompassed 114 patients with an average age of 71 years, primarily focusing on evaluating its safety and long-term effectiveness.
The JensClip trials recorded a 97% device success rate at 30 days post-operation, further supporting its clinical viability. Evaluating the safety indicators, the all-cause mortality was a mere 1.8%, with few complications reported, indicating a bot favorable and minimal risk profile.
Long-Term Efficacy Data
Over a year, significant improvements were reported in the mitral regurgitation grade, alongside a notable enhancement in patients' quality of life metrics. An impressive 96.29% of participants demonstrated no above-moderate mitral regurgitation post-treatment. These outcomes clearly underscore Jenscare's commitment to providing transformative heart treatments.
Professor Xiangbin Pan highlighted the JensClip's innovative design, emphasizing its reliability and ease of use for practitioners. The clinical results reaffirm that JensClip is not just a device, but a comprehensive solution catered to patients at high surgical risk.
About the Innovative Devices
LuX-Valve Plus represents Jenscare's commitment to tackling complex tricuspid valve cases. By integrating advanced technological features, it aims to enhance outcomes for high-risk patients significantly. The recent study results bolster LuX-Valve's role in reshaping treatment paradigms for severe tricuspid regurgitation.
On the other hand, the JensClip system boasts an inventive self-locking mechanism aimed at improving surgical outcomes and efficiency. The design promotes optimal safety measures, enhancing the ease of maneuverability during procedures. As a result, it stands as a testament to Jenscare’s innovative spirit in the realm of cardiac healthcare.
About Jenscare: Pioneers in Medical Innovation
Founded in 2011, Jenscare has rapidly ascended to the forefront of medical device innovation, focusing on interventional solutions for heart valve diseases. Their extensive portfolio highlights their dedication to developing state-of-the-art products that cater to various complexities in structural heart conditions. With over 700 implantation cases completed globally using the LuX-Valve series, Jenscare is poised to redefine the standards for heart valve replacement therapies.
Frequently Asked Questions
What is the LuX-Valve Plus?
The LuX-Valve Plus is an innovative self-developed system designed for treating severe tricuspid regurgitation in high-risk patients.
What were the key findings from the TRINITY trial?
The TRINITY trial demonstrated a near 97% device success rate within 30 days and significant improvement in patient quality of life, enabling effective management of tricuspid regurgitation.
What outcomes were observed for the JensClip?
The JensClip showed a 97% success rate at 30 days with a 1.8% mortality rate, alongside ongoing significant improvements in patient quality of life over a year.
How many patients were involved in the studies?
The TRINITY trial included 161 patients, while the JensClip study involved 114 participants.
What distinguishes Jenscare as a company?
Jenscare is recognized for its innovative approaches to interventional treatments for heart diseases, particularly its strong focus on developing groundbreaking products in structural heart disease solutions.
